Pfizer Inc.

Company Snapshot

Founded: 1849
Entity Type: Public
Employees: 81,000
Region: U.S.
Revenue: $63,627.0 Millions
Revenue Year: 2024
Segment: Biopharma
Headquarter: New York, U.S.
Key Geographics: U.S., Developed Europe, Developed Rest of World
Corporate Address: 66 Hudson Boulevard East, New York, 10001-2192 U.S. Tel. +1-212-733-2323 www.pfizer.com

Company Overview

Pfizer is a global biopharmaceutical company founded in 1849. In 2021, Pfizer reorganized its commercial operations into two business units: Biopharma and Business innovation. The biopharma unit includes three customer groups: primary care, specialty care, and oncology. The biopharma segment offers drug and vaccine products across various therapeutic areas. Business innovation consists of two units: Pfizer CentreOne and Pfizer Ignite. Pfizer CentreOne provides contract development and manufacturing organization (CDMO) services and supplies specialty active pharmaceutical ingredients. Pfizer Ignite offers strategic guidance and R&D services to innovative biotech companies.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Pfizer Inc. In Reports

Global Oncology Biosimilars Market

According to BCC Research detailed report on oncology biosimilars market analysis was for the base year 2024, with projections for 2025 to 2030.

Global Markets and Technologies for Advanced Drug Delivery Systems - Focus on Routes of Administration

According to BCC Research detailed report on advanced drug delivery systems market estimates, data will be provided for 2024 because of the base year, with forecasts for 2025 and forecast value for 2030.

Botanical and Plant-derived Drugs: Global Markets

BCC Research detailed report on botanical and plant derived drugs market includes global revenue ($ Million) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030.

Company's Business Segments

  • Biopharma : Oncology: Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak Primary Care: Internal medicine: Eliquis, the Premarin family and BMP2 Migraine: Nurtec ODT/Vydura and Zavzpret. Vaccines: Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix and Trumenba Treatment for COVID-19: Paxlovid Detection of COVID-19 and influenza: Lucira by Pfizer Specialty Care: Inflammation & immunology: Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo and Velsipity Rare disease: the Vyndaqel family, Genotropin, BeneFIX, Oxbryta, Somavert and Ngenla Hospital: Sulperazon, Zavicefta, Zithromax, Medrol and Panzyga
  • Other business activities : Oncology Research and Development (ORD), Pfizer Research and Development (PRD), Corporate and other unallocated (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement, among others) and other corporate costs.

Applications/End User Industries

  • Rare Disease
  • Internal Medicine
  • Inflammation
  • Immunology
  • Vaccines
  • Oncology
  • Anti Infectives
  • Healthcare
  • Pharmaceutical
AI Sentiment